Please use this identifier to cite or link to this item:
|Title:||COVID-19: uncovering individuality|
|Authors:||Cruz, Carolina Murici|
Freitas, Maria Goreti Rosa
Dale, Luiz Eduardo
Cruz, Luiz Eduardo da
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Transmissores de Hematozoários. Rio de Janeiro, RJ, Brasil.
Clinica Dale. Rio de Janeiro, RJ, Brasil.
Axis Biotec Brazil.
Universidade de São Paulo. São Paulo, SP, Brasil.
|Abstract:||SARS-Cov-2 is a virus easily transmitted by air and fomites causing acute severe respiratory syndrome. Severity in some cases requires hospitalization and complex expensive intensive care treatments. Its rampant contagious led to a a fearful pandemic affecting the whole world with millions of infected humans and almost half a million deaths in a few months in the beginning of 2020 (until June 17, 2020). SARS-Cov2 is likely to have been spilled over from natural sylvatic cycles in bats from China. Our purpose is to comment on the human individual immune inflammatory responses to the infection of SARS-Cov2 and the reflections of these individual immunoinflammatory profiles on patterns of the severity of the disease, time for therapeutical intervention, pathogenesis, candidate drugs and indicative comparative drug prices for covid-19. Efficient treatment for covid-19 may require: 1) early disease detection, 2) a combination of drugs being used for 3) targeting the virus replication cycle and 4) specific/ individualized drug treatment for given immunoinflammatory human profile responses in a 5) timely manner. Specific serum immuno-markers of covid-19 affected individuals at onset, in the follow-up, and in the resolution of the immunoinflammatory storm during the course of the disease may lead to individualized therapeutics with better outcomes. Covid-19 is unlikely to be the last emergent human disease with fast pandemic potencial. To gather knowledge on the human host profiles and immunoinflamatory responses is an opportunity that could pave the way to faster, more efficient strategies to tackle upcoming diseases.|
|Citation:||CRUZ, Carolina Murici et al. COVID-19: Uncovering Individuality, p. 1-7, June 2020.|
|Description:||Maria Goreti Rosa Freitas - Fundação Oswaldo Cruz. Instituto Oswaldo Cruz, Laboratório de Transmissores de Hematozoários. Rio de Janeiro, RJ, Brasil. Documento produzido em parceria ou por autor vinculado à Fiocruz, mas não consta à informação no documento.|
|Appears in Collections:||IOC - Preprint|
Files in This Item:
|MariaGoreti_Rosa_etal_IOC_2020.pdf||559.3 kB||Adobe PDF||View/Open|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.